Skip to main content
. Author manuscript; available in PMC: 2014 May 7.
Published in final edited form as: RSC Adv. 2013 Oct 4;3(47):24794–24811. doi: 10.1039/C3RA43094D

Figure 1.

Figure 1

Synergism of co-delivery. A) Depiction of the synergistic mechanism of the co-delivered drugs DOX and AGM (left). Synergistic cytotoxic effect of linear HPMA copolymer-DOX-AGM when compared to conjugated DOX or combination delivery of separately-conjugated DOX and AGM (right). Reprinted18 with permission from Elsevier. B) Synergistic mechanism of the co-delivery of DOX and siRNA targeting the Bcl-2 gene (left). The synergistic impact on ovarian cancer cell viability of liposomal co-delivery of DOX and Bcl-2 siRNA (right). Reprinted11 with permission of John Wiley and Sons. C) Liposomal co-delivery of therapeutic plasmid pEGFP-hTRAIL and paclitaxel yields an increase in survival time for glioma-bearing mice. Reprinted16 with permission of Elsevier.